Cadrenal Therapeutics Inc... (CVKD)
17.71
0.25 (1.43%)
At close: Apr 02, 2025, 3:59 PM
17.59
-0.68%
After-hours: Apr 02, 2025, 07:00 PM EDT
1.43% (1D)
| Bid | 16.2 |
| Market Cap | 33.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -8.73 |
| PE Ratio (ttm) | -2.03 |
| Forward PE | -4.44 |
| Analyst | Strong Buy |
| Ask | 19 |
| Volume | 13,704 |
| Avg. Volume (20D) | 42,771 |
| Open | 17.23 |
| Previous Close | 17.46 |
| Day's Range | 16.92 - 19.03 |
| 52-Week Range | 5.40 - 22.90 |
| Beta | 1.45 |
About CVKD
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida....
Industry Biotechnology
Sector Healthcare
IPO Date Jan 20, 2023
Employees 4
Stock Exchange NASDAQ
Ticker Symbol CVKD
Website https://www.cadrenal.com
Analyst Forecast
According to 1 analyst ratings, the average rating for CVKD stock is "Strong Buy." The 12-month stock price forecast is $32, which is an increase of 80.69% from the latest price.
Stock Forecasts5 months ago
+17.97%
Cadrenal Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
